Souvenaid in the management of mild cognitive impairment: an expert consensus opinion

Jeffrey L. Cummings, Peter Passmore, Bernadette McGuinness, Vincent Mok, Christopher Chen, Sebastiaan Engelborghs, Mark Woodward, Sagrario Manzano, Guillermo García‐Ribas, Stefano F. Cappa, Paulo Henrique Ferreira Bertolucci, Leung‐Wing ChuAlzheimer 2019 · DOI

Abstract: Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using a multimodal management approach including lifestyle risk factor modification and consideration of the multinutrient Souvenaid.

Introduction

Mild Cognitive Impairment (MCI) represents a critical "window of opportunity" in the trajectory of neurodegenerative disease. While approximately 50% of MCI cases progress to dementia—most commonly Alzheimer’s Disease (AD)—this transition period allows for targeted interventions aimed at preserving brain health. However, clinical management is often hampered by diagnostic ambiguity in primary care and a perceived therapeutic gap, as no pharmacological "cures" currently exist for MCI.

To address these challenges, an international panel of specialists convened to establish an expert consensus. By reviewing clinical evidence from major randomized controlled trials (RCTs) and real-world practice, the panel evaluated the efficacy of various medical, lifestyle, and nutritional interventions.

The Rationale for Multinutrient Intervention

While single-nutrient supplements (such as Vitamin E or Omega-3 alone) have largely failed to show significant benefits in clinical trials, research suggests that a synergistic, multinutrient approach may be more effective. Souvenaid, containing the specific nutrient blend Fortasyn Connect, is designed to provide the precursors and cofactors required for the synthesis of neuronal membranes and synapses. This blend includes omega-3 fatty acids, uridine, choline, B vitamins, and antioxidants.

Evidence from the LipiDiDiet trial—a 24-month multicenter study targeting prodromal AD—demonstrated that early intervention is crucial. Souvenaid showed significant beneficial effects on cognition and function (measured by CDR-SOB and ADCOMS) and a reduced rate of hippocampal atrophy. Notably, these benefits are most pronounced in the "prodromal" or mild stages of AD; the intervention loses efficacy as the disease progresses to moderate stages.

A Multimodal Management Strategy

The consensus panel emphasizes that nutrition is not a standalone solution. Effective management of MCI requires a multimodal approach that addresses medical, lifestyle, and psychosocial factors alongside nutritional support.

Table 1: Consensus recommendations for MCI management interventions and their associated degrees of clinical confidence.

As shown in the table above, the panel assigned "degrees of confidence" to various recommendations. High confidence (+++) was attributed to optimizing blood pressure, smoking cessation, physical exercise, and treating depression/anxiety. Within the nutritional category, both adherence to specific diets (like Mediterranean or DASH) and the use of evidence-based supplements like Souvenaid received high confidence ratings.

Clinical Outcomes and Safety

The clinical relevance of Souvenaid is supported by a remarkably low "Number Needed to Treat" (NNT) for memory improvement, ranging between 6 and 21 across different studies. Furthermore, MRI imaging has provided structural evidence of its impact, showing a slowed rate of brain atrophy in the hippocampus. From a safety perspective, Souvenaid has proven to be as well-tolerated as a placebo, with high adherence rates observed in real-world clinical settings.

Limitations and Future Directions

Despite the promising data, several barriers remain. Primary care physicians often lack the specialized tools or time required for the detailed neuropsychological testing necessary for early MCI diagnosis. Additionally, while 24-month data is encouraging, the long-term impact (beyond 5 years) of nutritional intervention remains to be fully characterized. Future research should focus on identifying predictive biomarkers—such as CSF amyloid/tau or PET scans—to better identify which patients are most likely to benefit from this multimodal, multinutrient therapy.

Summary updated

Abstract

Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using a multimodal management approach including lifestyle risk factor modification and consideration of the multinutrient Souvenaid.
BibTeX
@inproceedings{cummings2019souvenaid,
  author = {Jeffrey L. Cummings and Peter Passmore and Bernadette McGuinness and Vincent Mok and Christopher Chen and Sebastiaan Engelborghs and Mark Woodward and Sagrario Manzano and Guillermo García‐Ribas and Stefano F. Cappa and Paulo Henrique Ferreira Bertolucci and Leung‐Wing Chu},
  title = {{Souvenaid in the management of mild cognitive impairment: an expert consensus opinion}},
  booktitle = {Alzheimer},
  year = {2019},
  doi = {10.1186/s13195-019-0528-6},
}
Figure